Please ensure Javascript is enabled for purposes of website accessibility
Maxx Chatsko

Maxx Chatsko

XMFBlacknGoldX

Maxx has been a contributor to Fool.com since 2013. He graduated from the State University of New York College of Environmental Science and Forestry (2012) with a Bachelor of Science in Bioprocess Engineering and from Carnegie Mellon University (2016) with a Master of Science in Materials Science & Engineering.

Recent articles

410 binoculars kid

What to Watch When Codexis Reports 2019 Operating Results

The stock has tumbled to start 2020. Can the next business update provide any relief to shareholders?


arrow up shelves

Here's Why Iovance Biotherapeutics Shares Soared as Much as 39.6%

Bloomberg reports that the company has been toying with the idea of a sale.


stock down erased chalkboard

Here's Why Guardant Health Tumbled Today

The company expects losses to more than double in 2020, which caught Wall Street analysts by surprise.


stock sliding chalkboard

Here's Why Clovis Oncology Lost as Much as 11.8% Today

Investors are nervous heading into the company's fourth-quarter and full-year 2019 earnings report.


chalkboard stock down pink

Here's Why Epizyme Is Tumbling Today

The pharma company released full-year 2019 operating results.

031 lithium brine

Lithium: 3 Things Investors Need to Know

Lithium is bound to be one of the most important materials of the 21st century. Is your portfolio positioned for the opportunity?


raining cash getty

Here's Why Aerie Pharmaceuticals Jumped as Much as 14.4% Today

The eye-care company reported better-than-expected fourth-quarter 2019 product revenue.


multiple lines down

Here's Why Livent Stock Tumbled Today

The lithium producer disappointed investors with initial full-year 2020 guidance and production delays, but its long-term potential remains intact.


063 2019 blocks

Repligen Signals Gene Therapy Strength With 2019 Earnings Report

Guidance for 2020 appears to have spooked investors, but the bioprocess leader is on a solid long-term trajectory.


chalkboard stock down pink

Here's Why Agenus Tumbled Today

Results from an experimental combination therapy were impressive, but they might not be impressive enough.

business growth

Here's Why Albemarle Rose as Much as 11.6% Today

Investors cheered the company's fourth-quarter and full-year 2019 earnings report.


businessman pulley stock down

Here's Why Invitae Stock Is Tumbling Today

The genetic testing company reported full-year 2019 operating results.


076 arrow dude getty

Here's Why Twist Bioscience Stock Rose as Much as 14.8% Today

The company announced a public offering of common stock.


paper airplanes rising

Here's Why SunPower Is Soaring Today

An industry peer echoed SunPower's previous comments that, at this time, the coronavirus epidemic in China isn't expected to have a major impact on first-quarter 2020 operations.


arrow up shelves

Agenus Stock Rises Ahead of Investor Day Presentation

The biopharma is scheduled to update investors and Wall Street analysts on two important pipeline programs on Feb. 20.

woman orange laptop excited

Here's Why Enphase Energy Stock Is Soaring Today

The solar hardware company reported full-year 2019 operating results.


600 scientist microscope

Here's Why Inovio Pharmaceuticals Popped Today

The pharmaceutical company received a lot of positive media attention over the weekend.


353 doctor boxing gloves

2 Top Stocks Under $20

These pharma stocks have gone in different directions in the last year, but both hold promise for forward-thinking investors.


302 yellow airplane unique

About to Buy Penny Stocks? Look at These 2 Companies First

These healthcare stocks offer high risk and high reward, but they aren't nearly as risky as penny stocks.


multiple lines down

Here's Why Avrobio Fell as Much as 16.4% Today

The small-cap biopharmaceutical company announced a public stock offering.